Table 1
Schedule of enrolment, interventions and assessments of the LAP-PIE trial
| Timepoint | Study period | |||||||||
| Enrolment | Allocation | Post-allocation follow-up time points | Close-out | |||||||
| -t1 | 0 | Pre-IRE | 6 hours post-IRE | 6 days post-IRE | 3 months | 6 months | 9 months | 12 months | ||
| Enrolment: | ||||||||||
| Eligibility screen | X | |||||||||
| PIS given | X | |||||||||
| Systemic treatment with FOLFIRINOX | X | |||||||||
| sMDT | X | |||||||||
| Informed consent | X | |||||||||
| Allocation | X | |||||||||
| Interventions: | ||||||||||
| IRE (intervention) | 
| |||||||||
| Systemic chemotherapy (SoC) |  | |||||||||
| Assessments: | ||||||||||
| CT CAP | X | X | X | X | X | |||||
| Blood tests | X | X | X | X | X | X | X | X | X | |
| HRQoL | X | X | X | X | X | |||||
| Complications | X | X | X | X | X | |||||
CT CAP, CT chest abdomen pelvis; FOLFIRINOX, 5-FluoroUracil, Leucovorin, Irinotecan and Oxaliplatin; HRQoL, health-related quality of life; IRE, irreversible electroporation; LAP-PIE, locally advanced pancreatic cancer with percutaneous irreversible electroporation; PIS, patient information sheet; sMDT, specialist multidisciplinary team; SoC, standard of care.